stockportfolio.pro
Eikon Therapeutics, Inc. (EIKN)
Healthcare · Biotechnology · NasdaqGS
Eikon Therapeutics, Inc. revenue & earnings — last 3 fiscal years
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Gross profit | — | — | — |
| Net income | $-242.00M | $-243.81M | $-324.25M |
| Net margin | — | — | — |
Source: Eikon Therapeutics, Inc. SEC filings (10-K).
Explore 3 years of Eikon Therapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track EIKN in your portfolio →
Eikon Therapeutics, Inc. financial history by metric
About Eikon Therapeutics, Inc.
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004 to address brain metastases and primary brain malignancies; EIK1005, a potent WRN helicase inhibitor and anti-tumor agent for MSI-high tumors; and EIK1006, a clinical candidate and next-generation androgen receptor antagonist with activity against multiple clinically emergent variants of androgen receptor. The company was incorporated in 2019 and is based in Millbrae, California.
Eikon Therapeutics, Inc. — frequently asked questions
What is Eikon Therapeutics, Inc.'s revenue?
Eikon Therapeutics, Inc. (EIKN) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is Eikon Therapeutics, Inc. profitable?
No — EIKN reported a net loss of $-324.25M in fiscal 2025.
What is EIKN's P/E ratio?
Eikon Therapeutics, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Eikon Therapeutics, Inc. have?
As of fiscal year 2025, EIKN carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Eikon Therapeutics, Inc.'s market cap?
Eikon Therapeutics, Inc. (EIKN) has a market capitalization of about $453.14M, based on the latest data in our nightly-refreshed cache.
When does Eikon Therapeutics, Inc.'s fiscal year end?
EIKN's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Eikon Therapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 3 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.